From the Journals: Editors’ Picks for November

Each month, the editors from the portfolio of scientific journals published by the American Association for Cancer Research (AACR) highlight one “must read” article from every journal issue, which we summarize here. This month’s edition is stuffed with studies relating to recent clinical trials, a preclinical investigation of NSAIDs for the inhibition of colon tumor progression, and many more. As always, articles featured here are freely available for a limited time.

Read More

AACR Journals Editors’ Picks for October

As October comes to a close, it’s time for our latest edition of Editors’ Picks. This monthly staple is a collection of 10 “must read” articles that have been hand-selected by the editors from the portfolio of journals published by the AACR. This month, featured articles include results from three clinical trials and a look at cancer disparities among American Indians and Alaska Natives, among others. As always, articles highlighted here are freely available for a limited time.

Read More

A Look at Liver Cancer

As Greek mythology tells us, the titan Prometheus was punished by the gods for giving fire to man. His sentence? Eternal torture. Each day, an eagle would eat his liver, which would grow back overnight, ready to be devoured by the eagle again the next day.

The liver’s ability to regenerate presumably evolved to protect it from damage from food toxins. However, chronic cycles of liver damage and regeneration can lead to aberrant replication and eventually the development of liver cancer.

Read More

Bringing Awareness to Breast Cancer in October

Breast cancer can be a scary diagnosis. Even though mortality rates have declined in recent years in the United States, it is estimated that over 40,000 women and roughly 500 men will die from breast cancer in 2019. Despite progress in developing new treatment modalities for patients with this disease, there is still substantial work to be done in the field.

Read More

From the Journals: Editors’ Picks for September

As we welcome the fall season, it’s time for our September edition of Editors’ Picks, a monthly collection of articles hand-picked by the editors of the eight scientific journals published by the AACR. This month, articles span from an assessment of a first-in-class antibody-drug conjugate targeting the antigen CD205 in xenograft models, to results from a clinical trial evaluating the dual inhibition of VEGFR2 and MET in patients with advanced solid tumors. Read on to learn about this month’s selections, which are freely available for a limited time.

Read More

July Editors’ Picks from AACR Journals

As a monthly staple on this blog, we feature the editors’ picks from the 10 journal issues published by the American Association for Cancer Research (AACR). This month, selections include two articles detailing laboratory culture methods to model human cancers, as well as results from two clinical trials, among other studies. Per usual, articles summarized here are freely available for a limited time.

Read More

Highlights from AACR Meeting Focusing on Environmental Carcinogenesis

Decades of research have led to the identification of an increasing number of cancer-causing substances in our environment. These substances, known as environmental carcinogens, can be found anywhere, including in our air, water, food, and workplace.

Despite the progress we have made in identifying and increasing awareness of such carcinogens, experts believe that we have a long way to go before we have fully delineated them and successfully regulated our exposures to reduce cancer incidence. Therefore, establishing methods to better identify all of the carcinogens in our environment, to measure our exposure to them, and to prevent cancer caused by them are areas of active investigation in the field.

Read More

June Editors’ Picks from AACR Journals

Back for the month of June are the editors’ picks from the eight scientific journals published by the American Association for Cancer Research (AACR). Selections this month range from the identification of a long noncoding RNA involved in the canonical TGFβ/Smad signaling pathway to results from a clinical trial for patients with neuroendocrine tumors, a rare cancer type. Articles highlighted below are freely available for a limited time.

Read More